GlaxoSmithKline shingles vaccine hits goal in major study
LONDON (Reuters) – An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The vaccine, known as HZ/su, reduced the risk of shingles by 97.2 percent in adults aged 50 years and older compared to placebo in the Phase III clinical trial involving more than 16,000 individuals, the drugmaker said on Thursday. …
